{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:20:39Z","timestamp":1788315639180,"version":"build-2803163510"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"3","funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Antibiotic resistance complicates treatment of urinary infections, particularly when these ascend above the bladder, with few oral options remaining. New oral \u03b2-lactamase inhibitor combinations present a potential answer, with ceftibuten\/avibactam\u2014now undergoing clinical trials\u2014widely active against strains with ESBLs and serine carbapenemases. To inform its development we undertook mutant selection studies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Single-step mutants were sought from Enterobacterales (n\u200a=\u200a24) with AmpC, ESBL, OXA-48 and KPC \u03b2-lactamases. MICs were determined by CLSI agar dilution. Illumina WGS of selected mutants (n\u200a=\u200a50) was performed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Even at low MIC multiples, mutant frequencies were mostly only c. 10\u22128. \u03b2-Lactamase structural mutants were obtained only from KPC and AmpC enzymes. The KPC mutants had Trp105Arg or Ser130Thr substitutions, causing only small MIC shifts; the AmpC mutant had an Asn346Trp replacement, as previously selected with other avibactam combinations. No ESBL mutants were obtained. Rather, from Escherichia coli, we predominantly selected mutants with modifications to ftsI, encoding penicillin-binding protein (PBP) 3. From Klebsiella pneumoniae and Enterobacter cloacae we predominantly obtained variants with modification of uptake and efflux components or their regulators. ftsI mutants lacked cross-resistance to other avibactam combinations; uptake mutants had broader MIC rises. A few putative mutants had other lesion(s) of uncertain significance, or grew as small, stressed colonies lacking detectable lesions.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>There seems little risk of ESBLs mutating to confer ceftibuten\/avibactam resistance, though some risk may apply for KPC and AmpC enzymes. The propensity to select E. coli ftsI\/PBP3 mutants is notable and was not seen with other avibactam combinations.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkae452","type":"journal-article","created":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T11:09:07Z","timestamp":1734001747000},"page":"645-656","source":"Crossref","is-referenced-by-count":4,"title":["Frequencies and mechanisms of mutational resistance to ceftibuten\/avibactam in Enterobacterales"],"prefix":"10.1093","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3908-8332","authenticated-orcid":false,"given":"Shazad","family":"Mushtaq","sequence":"first","affiliation":[{"name":"Antimicrobial Resistance and Healthcare Associated Infections Reference Unit, UK Health Security Agency , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Vickers","sequence":"additional","affiliation":[{"name":"Antimicrobial Resistance and Healthcare Associated Infections Reference Unit, UK Health Security Agency , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Doumith","sequence":"additional","affiliation":[{"name":"STI Reference Laboratory, UK Health Security Agency , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Garello","sequence":"additional","affiliation":[{"name":"Antimicrobial Resistance and Healthcare Associated Infections Reference Unit, UK Health Security Agency , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Woodford","sequence":"additional","affiliation":[{"name":"Antimicrobial Resistance and Healthcare Associated Infections Reference Unit, UK Health Security Agency , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M","family":"Livermore","sequence":"additional","affiliation":[{"name":"Norwich Medical School, University of East Anglia , Floor 2, Bob Champion Research & Educational Building, James Watson Road, Norwich NR4 7UQ ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,12,12]]},"reference":[{"key":"2025030423054663200_dkae452-B1","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1080\/14787210.2023.2279104","article-title":"Treating urinary tract infections in the era of antibiotic resistance","volume":"21","author":"Frimodt-M\u00f8ller","year":"2023","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2025030423054663200_dkae452-B2","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1093\/jac\/dky453","article-title":"OXA-1 \u03b2-lactamase and non-susceptibility to penicillin\/\u03b2-lactamase inhibitor combinations among ESBL-producing Escherichia coli","volume":"74","author":"Livermore","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2025030423054663200_dkae452-B3","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1128\/CMR.00125-13","article-title":"Escherichia coli ST131, an intriguing clonal group","volume":"27","author":"Nicolas-Chanoine","year":"2014","journal-title":"Clin Microbiol Rev"},{"key":"2025030423054663200_dkae452-B4","doi-asserted-by":"publisher","first-page":"106574","DOI":"10.1016\/j.ijantimicag.2022.106574","article-title":"Susceptibility and resistance to fosfomycin and other antimicrobial agents among pathogens causing lower urinary tract infections: findings of the SURF study","volume":"59","author":"Tutone","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"2025030423054663200_dkae452-B5","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1007\/s40121-021-00509-4","article-title":"Oral antibiotics in clinical development for community-acquired urinary tract infections","volume":"10","author":"Veeraraghavan","year":"2021","journal-title":"Infect Dis Ther"},{"key":"2025030423054663200_dkae452-B6","doi-asserted-by":"publisher","first-page":"e00168-20","DOI":"10.1128\/AAC.00168-20","article-title":"Unorthodox parenteral \u03b2-lactam and \u03b2-lactamase inhibitor combinations: flouting antimicrobial stewardship and compromising patient care","volume":"64","author":"Palwe","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2025030423054663200_dkae452-B7","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.ijantimicag.2010.11.028","article-title":"Strategies to overcome extended-spectrum \u03b2-lactamases (ESBLs) and AmpC \u03b2-lactamases in shigellae","volume":"37","author":"Livermore","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"2025030423054663200_dkae452-B8","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s10096-023-04562-4","article-title":"Antimicrobial activity of ceftibuten-avibactam against a global collection of Enterobacterales from patients with urinary tract infections","volume":"42","author":"Sader","year":"2023","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2025030423054663200_dkae452-B9","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1093\/jac\/dks079","article-title":"Characterization of \u03b2-lactamase and porin mutants of Enterobacteriaceae selected with ceftaroline + avibactam (NXL104)","volume":"67","author":"Livermore","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"2025030423054663200_dkae452-B10","doi-asserted-by":"publisher","first-page":"5324","DOI":"10.1128\/AAC.00678-15","article-title":"In vitro selection of ceftazidime-avibactam resistance in Enterobacteriaceae with KPC-3 carbapenemase","volume":"59","author":"Livermore","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2025030423054663200_dkae452-B11","doi-asserted-by":"publisher","first-page":"3336","DOI":"10.1093\/jac\/dky363","article-title":"Selection of mutants with resistance or diminished susceptibility to ceftazidime\/avibactam from ESBL- and AmpC-producing Enterobacteriaceae","volume":"73","author":"Livermore","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2025030423054663200_dkae452-B12","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1093\/jac\/dkab346","article-title":"Selection and characterization of mutational resistance to aztreonam\/avibactam in \u03b2-lactamase-producing Enterobacterales","volume":"77","author":"Mushtaq","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2025030423054663200_dkae452-B13","doi-asserted-by":"publisher","first-page":"e02097-16","DOI":"10.1128\/AAC.02097-16","article-title":"Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2025030423054663200_dkae452-B14","author":"CLSI","year":"2018"},{"key":"2025030423054663200_dkae452-B15","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1093\/bioinformatics\/btu153","article-title":"Prokka: rapid prokaryotic genome annotation","volume":"30","author":"Seemann","year":"2014","journal-title":"Bioinformatics"},{"key":"2025030423054663200_dkae452-B16","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1042\/bj2760269","article-title":"A standard numbering scheme for the class A beta-lactamases","volume":"276","author":"Ambler","year":"1991","journal-title":"Biochem J"},{"key":"2025030423054663200_dkae452-B17","doi-asserted-by":"publisher","first-page":"e01841-19","DOI":"10.1128\/AAC.01841-19","article-title":"A standard numbering scheme for class C \u03b2-lactamases","volume":"64","author":"Mack","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2025030423054663200_dkae452-B18","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.resmic.2005.11.014","article-title":"Non-essential KDO biosynthesis and new essential cell envelope biogenesis genes in the Escherichia coli yrbG-yhbG locus","volume":"157","author":"Sperandeo","year":"2006","journal-title":"Res Microbiol"},{"key":"2025030423054663200_dkae452-B19","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/j.1574-6968.2010.01906.x","article-title":"The complexity of the \u2018simple\u2019 two-component system KdpD\/KdpE in Escherichia coli","volume":"304","author":"Heermann","year":"2010","journal-title":"FEMS Microbiol Lett"},{"key":"2025030423054663200_dkae452-B20","doi-asserted-by":"publisher","first-page":"e00008","DOI":"10.1128\/cmr.00008-23","article-title":"Klebsiella pneumoniae carbapenemase variants: the new threat to global public health","volume":"36","author":"Ding","year":"2023","journal-title":"Clin Microbiol Rev"},{"key":"2025030423054663200_dkae452-B21","doi-asserted-by":"publisher","first-page":"12916","DOI":"10.1038\/s41598-018-31176-0","article-title":"Defining the architecture of KPC-2 carbapenemase: identifying allosteric networks to fight antibiotics resistance","volume":"8","author":"Galdadas","year":"2018","journal-title":"Sci Rep"},{"key":"2025030423054663200_dkae452-B22","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.retram.2019.05.003","article-title":"Structure-based classification of class A beta-lactamases, an update","volume":"67","author":"Philippon","year":"2019","journal-title":"Curr Res Transl Med"},{"key":"2025030423054663200_dkae452-B23","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1093\/jac\/dkx035","article-title":"WCK 4234, a novel diazabicyclooctane potentiating carbapenems against Enterobacteriaceae, Pseudomonas and Acinetobacter with class A, C and D \u03b2-lactamases","volume":"72","author":"Mushtaq","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2025030423054663200_dkae452-B24","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1128\/AAC.01947-13","article-title":"Efficacy of humanized carbapenem and ceftazidime regimens against Enterobacteriaceae producing OXA-48 carbapenemase in a murine infection model","volume":"58","author":"Wiskirchen","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2025030423054663200_dkae452-B25","doi-asserted-by":"publisher","first-page":"e00216","DOI":"10.1128\/aac.00216-22","article-title":"OXA-48-like \u03b2-lactamases: global epidemiology, treatment options, and development pipeline","volume":"66","author":"Boyd","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2025030423054663200_dkae452-B26","doi-asserted-by":"publisher","first-page":"e98042","DOI":"10.1371\/journal.pone.0098042","article-title":"Crystal structure of penicillin-binding protein 3 (PBP3) from Escherichia coli","volume":"9","author":"Sauvage","year":"2014","journal-title":"PLoS One"},{"key":"2025030423054663200_dkae452-B27","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1093\/jac\/dku568","article-title":"Characterization of Escherichia coli NDM isolates with decreased susceptibility to aztreonam\/avibactam: role of a novel insertion in PBP3","volume":"70","author":"Alm","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2025030423054663200_dkae452-B28","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1093\/cid\/ciz1131","article-title":"Early experience with meropenem-vaborbactam for treatment of carbapenem-resistant Enterobacteriaceae infections","volume":"71","author":"Shields","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025030423054663200_dkae452-B29","doi-asserted-by":"publisher","first-page":"32571","DOI":"10.1074\/jbc.M114.565762","article-title":"The CpxR\/CpxA two-component regulatory system up-regulates the multidrug resistance cascade to facilitate Escherichia coli resistance to a model antimicrobial peptide","volume":"289","author":"Weatherspoon-Griffin","year":"2014","journal-title":"J Biol Chem"},{"key":"2025030423054663200_dkae452-B30","doi-asserted-by":"publisher","first-page":"e00109","DOI":"10.1128\/JB.00109-21","article-title":"Mutational activation of antibiotic-resistant mechanisms in the absence of major drug efflux systems of Escherichia coli","volume":"203","author":"Cho","year":"2021","journal-title":"J Bacteriol"},{"key":"2025030423054663200_dkae452-B31","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.mib.2004.02.010","article-title":"Control of the alternative sigma factor sigmaE in Escherichia coli","volume":"7","author":"Ades","year":"2004","journal-title":"Curr Opin Microbiol"},{"key":"2025030423054663200_dkae452-B32","doi-asserted-by":"publisher","first-page":"e97202","DOI":"10.1371\/journal.pone.0097202","article-title":"Resistance to \u03b2-lactam antibiotics conferred by point mutations in penicillin-binding proteins PBP3, PBP4 and PBP6 in Salmonella enterica","volume":"9","author":"Sun","year":"2014","journal-title":"PLoS One"},{"key":"2025030423054663200_dkae452-B33","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1038\/s41467-017-01835-3","article-title":"The genetic basis for the adaptation of E. coli to sugar synthesis from CO2","volume":"8","author":"Herz","year":"2017","journal-title":"Nat Commun"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/3\/645\/61084679\/dkae452.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/3\/645\/61084679\/dkae452.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T23:05:58Z","timestamp":1741129558000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/3\/645\/7922150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,12]]},"references-count":33,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,12,12]]},"published-print":{"date-parts":[[2025,3,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkae452","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2024,12,12]]}}}